1 Cassileth PA, "Varying intensity of postremission therapy in acute myeloid leukemia" 79 : 1924-1930, 1992
2 Pui CH, "Treatment of acute lymphoblastic leukemia" 354 : 166-178, 2006
3 Nagai S, "Risk-adapted maintenance therapy for acute promyelocytic leukemia" 28 : 21-, 2010
4 Bennett JM, "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group" 33 : 451-458, 1976
5 Patel JP, "Prognostic relevance of integrated genetic profiling in acute myeloid leukemia" 366 : 1079-1089, 2012
6 Karp JE, "Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features" 14 : 3077-3082, 2008
7 Löwenberg B, "Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group" 16 : 872-881, 1998
8 Krug U, "Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?" 17 : 85-90, 2010
9 Robles C, "Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia : an Eastern Cooperative Oncology Group Trial(E5483)" 14 : 1349-1353, 2000
10 Baer MR, "Is there a role for maintenance therapy in acute myeloid leukaemia?" 22 : 517-521, 2009
1 Cassileth PA, "Varying intensity of postremission therapy in acute myeloid leukemia" 79 : 1924-1930, 1992
2 Pui CH, "Treatment of acute lymphoblastic leukemia" 354 : 166-178, 2006
3 Nagai S, "Risk-adapted maintenance therapy for acute promyelocytic leukemia" 28 : 21-, 2010
4 Bennett JM, "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group" 33 : 451-458, 1976
5 Patel JP, "Prognostic relevance of integrated genetic profiling in acute myeloid leukemia" 366 : 1079-1089, 2012
6 Karp JE, "Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features" 14 : 3077-3082, 2008
7 Löwenberg B, "Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group" 16 : 872-881, 1998
8 Krug U, "Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?" 17 : 85-90, 2010
9 Robles C, "Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia : an Eastern Cooperative Oncology Group Trial(E5483)" 14 : 1349-1353, 2000
10 Baer MR, "Is there a role for maintenance therapy in acute myeloid leukaemia?" 22 : 517-521, 2009
11 Büchner T, "Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia(AML) : two multicenter studies of the German AML Cooperative Group" 3 : 1583-1589, 1985
12 British Committee for Standards in Haematology, "Guidelines on the management of acute myeloid leukaemia in adults" 135 : 450-474, 2006
13 Clift RA, "Follow-up 26 years after treatment for acute myelogenous leukemia" 351 : 2456-2457, 2004
14 Büchner T, "Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia" 24 : 2480-2489, 2006
15 Burnett AK, "Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission" 31 : 1293-1301, 2013
16 Preisler H, "Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia : a cancer and leukemia group B study" 69 : 1441-1449, 1987
17 Mrózek K, "Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?" 109 : 431-448, 2007
18 이현규, "Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis" 대한혈액학회 49 (49): 95-99, 2014
19 Cassileth PA, "Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission" 339 : 1649-1656, 1998
20 Deschler B, "Acute myeloid leukemia : epidemiology and etiology" 107 : 2099-2107, 2006
21 Estey EH, "Acute myeloid leukemia : 2014 update on risk-stratification and management" 89 : 1063-1081, 2014
22 Löwenberg B, "Acute myeloid leukemia" 341 : 1051-1062, 1999
23 Sauter C, "Acute myelogenous leukaemia : maintenance chemotherapy after early consolidation treatment does not prolong survival" 1 : 379-382, 1984
24 Avvisati G, "AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia : very long-term results and role of maintenance" 117 : 4716-4725, 2011
25 Miyawaki S, "A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study" 104 : 2726-2734, 2005
26 Asou N, "A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy : the Japan Adult Leukemia Study Group(JALSG)APL97 study" 110 : 59-66, 2007
27 Fenaux P, "A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group" 94 : 1192-1200, 1999
28 Büchner T, "6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group" 21 : 4496-4504, 2003